Early prediction of response to cetuximab and radiotherapy by FDG-PET/CT for the treatment of a locoregionally advanced squamous cell carcinoma of the hypopharynx
Cetuximab (CTX) is used for the concurrent treatment with radiotherapy (RT) in squamous cell carcinoma of head and neck (HNSCC). There are no reliable clinical predictive markers of effectiveness of CTX at yet. We describe the clinical case of patient who received a CTX/RT to cure locoregionally adv...
Main Authors: | Mindaugas Grybauskas, Jean-François Daisne, Eduardas Aleknavičius, Arvydas Burneckis |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2014-01-01
|
Series: | Medicina |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1010660X14000688 |
Similar Items
-
Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
by: Tien-Hua Chen, et al.
Published: (2022-12-01) -
Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
by: Juan A. Marín-Jiménez, et al.
Published: (2022-07-01) -
Post-treatment surveillance of head and neck cancer: pitfalls in the interpretation of FDG PET-CT/MRI
by: Christian Martin Meerwein, et al.
Published: (2015-02-01) -
PET Imaging Biomarkers of Anti-EGFR Immunotherapy in Esophageal Squamous Cell Carcinoma Models
by: Tae Sup Lee, et al.
Published: (2018-10-01) -
The dogma of Cetuximab and Radiotherapy in head and neck cancer – A dawn to dusk journey
by: Sapna Krishnamurthy, et al.
Published: (2022-05-01)